AMR Conference in Berlin: Call for better incentives
More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR).
Biomarker can exclude acute kidney injury
Researchers target neuroblastoma with ALK-ADC
Researchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated ALK.
AMR: Germany set to invest 39m into CARB-X
Global antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership.
AstraZeneca partners with Seres Therapeutics
Under a three-year agreement, British pharma giant AstraZeneca plc pays 20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response to cancer immune therapies.
Small-molecule acts as broad-band influenza entry blocker
Researchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure starts second microbiome-focussed fund
Seventure Partners has announced the first close of its second microbiome fund designed to put 200m in 20 companies developing microbiome-based health solutions.
EMA approves eight meds for market
The EMAs human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authorisation.
Genfit set to raise $100m in Nasdaq IPO
French Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US.
Targeting NFkappaB protects tendons from injury
Researchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.